Other Relevant Adverse Effects Additional side effects that may indirectly affect energy include: Fatigue (listed as a common adverse reaction for Wegovy) Decreased appetite (very common, often therapeutic but may lead to inadequate nutrition) Headache (reported in clinical trials) Dizziness (may be related to dehydration or blood pressure changes) Gallbladder problems (including gallstones, which may present with fatigue and abdominal pain) While these effects do not constitute direct sedation or drowsiness, their cumulative impact on physical well-being can manifest as reduced energy and increased tiredness
Again, thyroid function testing can distinguish between the two causes, though in practice, many tirzepatide users with normal thyroid function still report feeling cold as they lose weight
( 90 % of the metabolism is the combined expenditure of the heart, lungs, brain, kidneys and liver) Reduced NEAT (non-exercise activity thermogenesis): You move less throughout the day without realizing it
Cut your portion sizes by 30% to 50%, especially during the first two weeks after a dose increase
Retatrutide Side Effects (Preliminary Data) Common (from Phase 2 data): Nausea (25-45% depending on dose) Diarrhea (20-35%) Vomiting (10-20%) Constipation (10-15%) Decreased appetite Notable differences: Mild increases in resting heart rate observed The glucagon receptor component may introduce metabolic effects not seen with GLP-1-only medications Full safety profile awaiting Phase 3 data The overall tolerability of retatrutide in the Phase 2 trial was described as acceptable, with most adverse events being mild to moderate
Medicare Ozempic is covered under most Medicare plans
